25th Annual Market Access Summit 2026 | Day 1

Gain insight into today’s sessions so you can get the most out of your conference experience.

Health Canada has responded to Stakeholder concerns about timely access by patients to life-saving therapies by launching initiatives designed to improve market access. Adapt your market access strategy to the latest advances in regulatory reductions.  Take back to your team ideas to help you: 

• Understand how the Red Tape Review launched on July 9, 2025 could positively impact your market access plans 
• Navigate an increasingly flexible clinical trial environment 
• Analyze how the first Ministerial Reliance Order provides new submission opportunities 

Develop a roadmap for aligning your 2027 clinical and regulatory strategy with Canada’s increasingly agile and patient-centric approval landscape. 

Value recognition is a critical factor in Canada’s ability to attract and sustain access to innovative medicines.  HTA agencies are fundamental to establishing value recognition by acting as system conveners and bringing together all stakeholders to create a foundational understanding of value that is incorporated into carried through the entire reimbursement process.  Take away actionable strategies to help you: 

• Explore how HTA frameworks are evolving to more fully and accurately capture the value of innovation, and examine what adaptations are needed to remain relevant, transparent, and impactful in a rapidly changing healthcare environment. 
• Examine how value recognition established through HTA is leveraged by payers and how the alignment between HTA assessments and provincial reimbursement decisions can be strengthened to support both timely patient access and system sustainability. 

Understand trends in value recognition and strengthen your submission for reimbursement – it has never mattered more. 

Enhance your progress and impact delivered in the first phase of the 2023–2030 strategy. You’ll walk away with a blueprint to: 

• Bolster how global policy and geopolitical shifts are influencing strategic direction. 
• Leverage how to embed new forms of evidence in practice for HTA and access. 
• Ensure you understand how evidence expectations are evolving across payers, regulators, and industry. 
• Master what interested parties should anticipate from Canada’s Drug Agency through to 2030. 

Gain clarity on progress to date and how embedding new forms of evidence will redefine access and decision-making through 2030. 

Master the 2026 negotiation logic that requires an understanding of the pCPA processes. You’ll walk away with a blueprint to:

• Mastering Accelerated Negotiation Pathways: Understanding and navigating expedited negotiations processes.

• Optimizing Process Integration: Minimize operational friction and drive stronger negotiation alignment and collaboration.

Identify the tactical adjustments and evidence requirements necessary for manufacturers to achieve successful, predictable outcomes in an increasingly complex and scrutinized payer environment.

• Browse through different sponsor booths and source innovative market access expertise.
• Enter your name for a chance to win exciting prizes.
• Take advantage of event-specific offers and special content.

The CUSMA trade talks and the National Pharmacare program that is fragmented and seemingly stalled have introduced considerable uncertainty into the marketplace and the path forward.  Gain a better understanding of the impact on manufacturers and how private insurers may respond.  Take away ideas to: 

• Assess the impact this uncertainty has on allocating coverage of some medications between national pharmacare where it exists and private plans  
• Determine what impact Trump’s MFN call could have on manufacturer’s pricing decisions and the approach private insurers may take in response 
• How private payers can improve plan sustainability 
• Understand what drugs and therapies private payers will continue to cover and their listing criteria to enhance your submissions   

Expand your understanding of how ongoing funding is contingent on real-world clinical performance. Explore how RWE in lifecycle management involves navigating the shift toward HTA reassessments. You’ll walk away with practical tips to: 

• Understand how HTA agencies are thinking about generative AI 
• Analyze practical applications of generative AI across the RWE and market access lifecycle (e.g., evidence synthesis, protocol development, and supporting HTA and reimbursement planning) 
• Determine where AI can realistically add value today, as well as its current limitations 
• Develop governance, transparency, validation, and human oversight when using AI-generated outputs 
• Establish data quality and interoperability as foundational requirements for AI-enabled evidence generation 

Determine the strategic investments and multi-stakeholder partnerships required for you to transition from reactive data collection to a proactive, AI-enabled evidence strategy. 

• Experience the next level of market access innovation firsthand.
• Meet one-on-one with leading solution providers to discuss organizational hurdles.
• Brainstorm solutions and gain new perspectives and ideas.

Identify how IRP frameworks are evolving under increasing global pressure and what MFN policies change vs. traditional reference pricing. Create a roadmap to: 

• Eliminate the risk of accelerated price convergence across markets. 
• Master the implications for Canadian pricing strategy and global positioning. 
• Master how you adapt to manage pricing corridors and spillover risk.

Identify the implications for your launch sequencing, price sustainability, and navigating increasing cross-market dependencies 

The challenge in Canada is rarely a lack of evidence: It’s that different decision-makers require different answers from the same evidence package. Most clinical and economic evidence is developed from a global perspective, while Canadian access decisions are made within a uniquely fragmented public and private payer environment. Take back to your team valuable insights you can use to help you: 

• Understand how the evolution of international policies and priorities will impact evidence requirements for Canada 
• Navigate the misalignments between global evidence strategies and local decision-making needs  
• Take advantage of as emerging opportunities to leverage new forms of evidence to better support market access strategies in Canada 

Translate global market access successes into actionable, local initiatives that expedite patient access and improve your portfolio viability in the Canadian market.  

Timely patient access and a value-based proposal can coexist. Advance your understanding of risk-sharing and value-based contracts. Walk away with actionable tips to: 

• Bolster proven performance models by evaluating which risk-sharing structures, financial vs. outcomes-based, are being used. 
• Optimize data infrastructure requirements and address the gaps in provincial health data. 
• Amplify the payer perspective on risk and better understand how provincial ministries and private payers define and mitigate “uncertainty” in curative therapies. 
• Improve administrative feasibility and streamline the monitoring and reconciliation processes. 

Determine the core components of a successful value-based proposal that satisfies your fiscal requirements of the payers while ensuring timely patient access. 

Examine the IQSSS decision matrix and analyze the operational changes in the drug evaluation process. Optimize how you navigate the transition to IQSSS. Adopt best practices to: 

• Impact the new institute’s mandate on HTA timelines and transparency. 
• Improve “social and preventive” value, benchmarking the increased weighting of public health data and disease prevention. 
• Transform the 2027 submission cycle by identifying critical success factors for new drug submissions.  
• Amplify santé Québec and institutional governance, evaluating the new relationship in drug procurement and hospital access. 
• Enhance the “Quebec Advantage” by formulating strategies to preserve accelerated access timelines within its modernized health and social services infrastructure. 

Determine the requirements for recalibrating Quebec market access strategies to ensure your continuous alignment with the province’s evolving HTA leadership and fiscal priorities. 

Review the key solutions and takeaways from today’s sessions. Source a summary of action points to implement in your work. Discuss tomorrow’s highlights!